601607 上海医药
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入141,592,7831.56%275,250,935260,295,089231,981,300215,824,259
减:营业总成本137,611,8812.02%267,676,307253,008,864224,907,251209,641,475
    其中:营业成本126,660,0612.77%244,619,261228,966,947201,494,923187,281,149
               财务费用749,7756.21%1,480,9121,485,7581,313,1921,245,369
               资产减值损失(410,078)1,022.70%(614,374)(561,277)(331,471)(140,441)
公允价值变动收益75,752-33.72%203,854404,731218,738(206,004)
投资收益3,257,3331,222.17%380,427(68,123)533,1171,811,394
    其中:对联营企业和合营企业的投资收益380,6644.12%521,909129,329526,743789,596
营业利润6,833,62041.46%8,140,7137,667,2359,014,6508,205,486
利润总额6,820,82141.45%8,020,0077,054,2978,808,3538,143,815
减:所得税费用1,826,03749.11%2,149,9951,887,7261,816,3391,869,245
净利润4,994,78438.85%5,870,0115,166,5706,992,0156,274,569
减:非控股权益535,919-18.24%1,317,4831,398,5711,374,8631,181,102
股东净利润4,458,86551.56%4,552,5283,768,0005,617,1525,093,467

市场价值指针
每股收益 (元) *1.20051.90%1.2301.0201.6101.790
每股派息 (元) *----0.3700.4100.6100.420
每股净资产 (元) *20.2507.15%19.33018.50018.13717.367
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容